```markdown
---
application_number: 213260Orig1s000
document_type: Complete Response Letter
agency: U.S. Food and Drug Administration
center: Center for Drug Evaluation and Research
division: Division of Diabetes, Lipid Disorders, and Obesity
office: Office of Cardiology, Hematology, Endocrinology, and Nephrology
signed_by: John Sharretts, M.D.
signature_date: 2020-10-16T17:07:32-05:00
contact:
  name: Martin White, M.S.
  role: Regulatory Project Manager
  phone: (240) 402-6018
---

# CENTER FOR DRUG EVALUATION AND RESEARCH

## Critical Data

- **Application Number**: 213260Orig1s000  
- **Document Type**: Complete Response Letter  
- **Center**: Center for Drug Evaluation and Research  
- **Office**: Office of Cardiology, Hematology, Endocrinology, and Nephrology  
- **Division**: Division of Diabetes, Lipid Disorders, and Obesity  
- **Signed By**: John Sharretts, M.D.  
- **Signature Date**: October 16, 2020  
- **Contact**:  
  - Name: Martin White, M.S.  
  - Phone: (240) 402-6018  
  - Title: Regulatory Project Manager  
- **Status**: Not Approved - Additional Information Required  
- **Action Required**: Resubmission within 1 year; address all deficiencies  
- **Reference Regulations**:  
  - 21 CFR §314.50  
  - 21 CFR §314.65  
  - 21 CFR §314.110  
  - 21 CFR §25.30, §25.31, §25.40  

---

## U.S. Food and Drug Administration  
Silver Spring, MD 20993  
www.fda.gov

---

## Complete Response Letter

Satisfactory resolution of the following objectionable conditions is required (e.g., preapproval inspection and/or adequate facility responses addressing these conditions) before this application may be approved.

If it is determined that an inspection is needed to approve your application, please note that FDA continues to monitor the public health situation as well as travel restrictions. We are actively working to define an approach for scheduling outstanding inspections, once safe travel may resume and based on public health need and other factors.

For more information, please see the FDA guidances related to COVID-19. These guidances can be found at:

https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders

---

### 3. Facility Observations

Satisfactory resolution of the observations noted at the manufacturing facility is required before this NDA may be approved. Please list communications submitted to, or held with, the Agency to facilitate resolution of the observed objectionable conditions or deficiencies noted at the facility.

---

### 4. Reformulation and Bioequivalence

Reformulate the proposed product and conduct additional relative bioavailability studies to demonstrate the bioequivalence to the listed drug or conduct a clinical study to support the effective and safe use of the proposed atorvastatin oral suspension product.

---

## PRESCRIBING INFORMATION

We reserve comment on the proposed labeling until the application is otherwise adequate. We encourage you to review the labeling review resources on the following websites:

- [PLR Requirements for Prescribing Information](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084159.htm)
- [Pregnancy and Lactation Labeling Final Rule](http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm)

These resources include regulations, related guidance documents, and the Selected Requirements for Prescribing Information (SRPI) checklist.

If you revise labeling, use the SRPI checklist to ensure that the Prescribing Information conforms with format items in regulations and guidances.

Your response must include updated content of labeling ([21 CFR 314.50(l)(1)(i)]) in structured product labeling (SPL) format as described at:

https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

---

## PROPRIETARY NAME

The review of your proposed proprietary name has been terminated due to the deficiencies with the application as described in this letter.

Please resubmit the proposed proprietary name when you respond to the application deficiencies.

---

## SAFETY UPDATE

When you respond to the above deficiencies, include a safety update as described at [21 CFR 314.50(d)(5)(vi)(b)].

The safety update should include data from all nonclinical and clinical studies/trials of the product under consideration regardless of indication, dosage form, or dose level.

1. Describe in detail any significant changes or findings in the safety profile.

2. When assembling sections:
   - Discontinuations due to adverse events
   - Serious adverse events
   - Common adverse events

   Incorporate new safety data:
   - Present new safety data from studies/clinical trials for the proposed indication using the same format as in the original submission.
   - Present tabulations of new safety data combined with original application data.
   - Include tables that compare frequencies of adverse events in the original submission with new data.
   - For other indications, provide separate tables for adverse event frequencies in clinical trials.

3. Present a retabulation of the reasons for premature trial discontinuation, incorporating drop-outs from newly completed trials. Describe any new trends or patterns.

4. Provide:
   - Case report forms
   - Narrative summaries for each patient who died during a trial or who discontinued due to an adverse event.
   - Narrative summaries for serious adverse events.

5. Describe any information suggesting a substantial change in the incidence of common but less serious adverse events between new and original data.

6. Provide updated exposure information (e.g., number of subjects, person-time).

7. Provide a summary of worldwide experience with the product’s safety, including updated usage estimates for markets outside the U.S.

8. Provide English translations of current approved foreign labeling not previously submitted.

---

## ADDITIONAL COMMENTS

We have the following comment/recommendation:

We acknowledge the environmental analysis submitted under eCTD module section 1.12.14. As per 21 CFR 314.50(d)(1)(iii), an environmental assessment exemption request should be completed in accordance with 21 CFR §25.30, §25.31, or §25.40. Please resubmit your environmental assessment exception request accordingly.

---

## OTHER

Within one year after the date of this letter, you are required to resubmit or take other action under 21 CFR 314.110. Failure to respond may be considered a request to withdraw the application under 21 CFR 314.65.

You may request an extension of time to resubmit.

A resubmission must:

- Fully address all deficiencies listed in this letter
- Be clearly marked with "RESUBMISSION" in large font, bolded type at the beginning of the cover letter
- Clearly state that you consider this a complete response to the deficiencies outlined in this letter

Note: A partial response will not be processed as a resubmission and will not start a new review cycle.

You may request a meeting or teleconference with the FDA to discuss what steps are needed before the application may be approved.

Refer to the draft guidance:  
Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products.

> The drug product may not be legally marketed until you have been notified in writing that this application is approved.

---

## Contact Information

If you have any questions, contact:

> Martin White, M.S.  
> Regulatory Project Manager  
> (240) 402-6018

---

## Signed By

**John Sharretts, M.D.**  
Deputy Director  
Division of Diabetes, Lipid Disorders, and Obesity  
Office of Cardiology, Hematology, Endocrinology, and Nephrology  
Center for Drug Evaluation and Research

---

This is a representation of an electronic record that was signed electronically.

**Electronic Signature:**  
`/s/`  
**JOHN M SHARRETTS**  
**10/16/2020 05:07:32 PM**  
Signature Page 1 of 1
```